{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T18:19:55Z","timestamp":1774376395710,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T00:00:00Z","timestamp":1591315200000},"content-version":"am","delay-in-days":370,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.therap.2018.09.070","type":"journal-article","created":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T13:40:13Z","timestamp":1538055613000},"page":"383-388","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Am\u00e9liorer la balance b\u00e9n\u00e9fices\/risques de la m\u00e9thadone en respectant ses sp\u00e9cificit\u00e9s pharmacologiques"],"prefix":"10.1016","volume":"74","author":[{"given":"Elisabeth","family":"Frauger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Fouilh\u00e9 Sam-La\u00ef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Mallaret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00eblle","family":"Micallef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.therap.2018.09.070_bib0150","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2515\/therapie\/2015015","article-title":"New methadone formulation in France: results from 5\u00a0years of utilization","volume":"70","author":"Boucherie","year":"2015","journal-title":"Therapie"},{"issue":"2","key":"10.1016\/j.therap.2018.09.070_bib0155","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2515\/therapie\/2013020","article-title":"New formulation of methadone for opioid dependence in France: acceptability and diversion\/misuse liability","volume":"68","author":"Eiden","year":"2013","journal-title":"Therapie"},{"issue":"6","key":"10.1016\/j.therap.2018.09.070_bib0160","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2515\/therapie\/2012072","article-title":"Methadone-related deaths in Montpellier and Region, from 2000\u00a0to 2010","volume":"67","author":"Eiden","year":"2012","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2018.09.070_bib0165","article-title":"Opioid maintenance therapy in France: high-dosage buprenorphine still predominant despite a high increase in methadone use: results from the 2009-2015\u00a0UTOPIA study","author":"Maumus-Roberta","year":"2018","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.therap.2018.09.070_bib0170","series-title":"Comit\u00e9 technique des centres d\u2019evaluation et d\u2019information sur la pharmacod\u00e9pendance addictovigilance du 11\u00a0janvier 2018","author":"ANSM.","year":"2018"},{"key":"10.1016\/j.therap.2018.09.070_bib0175","series-title":"Commission stup\u00e9fiants et psychotropes du 1\u00a0f\u00e9vrier 2018","author":"ANSM","year":"2018"},{"key":"10.1016\/j.therap.2018.09.070_bib0180","author":"ANSM","year":"2018"},{"issue":"2","key":"10.1016\/j.therap.2018.09.070_bib0185","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2515\/therapie\/2015009","article-title":"Signal identification in addictovigilance: the functioning of the French system","volume":"70","author":"Jouanjus","year":"2015","journal-title":"Therapie"},{"issue":"4","key":"10.1016\/j.therap.2018.09.070_bib0190","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.therap.2017.01.010","article-title":"Surveillance system on drug abuse: interest of the French national OPPIDUM program of French addictovigilance network","volume":"72","author":"Frauger","year":"2017","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2018.09.070_bib0195","article-title":"Interest of take-home naloxone for opioid overdose","author":"Frauger","year":"2018","journal-title":"Therapie"},{"issue":"3","key":"10.1016\/j.therap.2018.09.070_bib0200","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.therap.2016.02.001","article-title":"Characteristics of subjects under opiate maintenance treatment in primary care using the OPEMA data 2013","volume":"71","author":"Gentile","year":"2016","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2018.09.070_bib0205","unstructured":"Centre d\u2019addictovigilance de Grenoble. D\u00e9c\u00e8s en relation avec l\u2019abus de m\u00e9dicaments et de substances\u00a0: principaux r\u00e9sultats de l\u2019enqu\u00eate DRAMES 2016. http:\/\/www.addictovigilance.fr\/drames.[Consult\u00e9 le 17\u00a0septembre 2018]."},{"key":"10.1016\/j.therap.2018.09.070_bib0210","unstructured":"Centre d\u2019addictovigilance PACA Corse. Les principaux faits marquants OPPIDUM 2017. http:\/\/www.addictovigilance.fr\/oppidum [Consult\u00e9 le 17\u00a0septembre 2018]."},{"issue":"4","key":"10.1016\/j.therap.2018.09.070_bib0215","first-page":"188","article-title":"Dans la douleur rebelle du cancer\u00a0: la m\u00e9thadone bien s\u00fbre\u00a0? Bien s\u00fbr\u00a0!","volume":"18","author":"Poulain","year":"2017","journal-title":"Douleurs\u00a0: Evaluation \u2013 Diagnostic \u2013 Traitement"},{"issue":"5051","key":"10.1016\/j.therap.2018.09.070_bib0220","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.15585\/mmwr.mm655051e1","article-title":"Increases in drug and opioid-involved overdose deaths \u2013 United States, 2010\u20132015","volume":"65","author":"Rudd","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"26","key":"10.1016\/j.therap.2018.09.070_bib0225","doi-asserted-by":"crossref","first-page":"667","DOI":"10.15585\/mmwr.mm6526a2","article-title":"Trends in methadone distribution for pain treatment, methadone diversion, and overdose deaths \u2013 United States, 2002\u20132014","volume":"65","author":"Jones","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.therap.2018.09.070_bib0230","series-title":"Public health advisory: methadone use for pain control might result in death and life-threatening changes in breathing and heartbeat","author":"Food and drug administration","year":"2006"},{"issue":"4","key":"10.1016\/j.therap.2018.09.070_bib0235","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jpain.2014.01.494","article-title":"Methadone safety: a clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collabration with the Heart Rhythm Society","volume":"15","author":"Chou","year":"2014","journal-title":"J Pain"},{"issue":"1","key":"10.1016\/j.therap.2018.09.070_bib0240","first-page":"14","article-title":"Methadone as an analgesic: a review of the risks and benefits","volume":"103","author":"Terpening","year":"2007","journal-title":"W V Med J"},{"key":"10.1016\/j.therap.2018.09.070_bib0245","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2225","article-title":"Factors associated with mortality in Scottish patients receiving methadone in primary care: retrospective cohort study","volume":"338","author":"McCowan","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.therap.2018.09.070_bib0250","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c4851","article-title":"Impact of supervision of methadone consumption on deaths related to methadone overdose (1993\u20132008): analyses using OD4\u00a0index in England and Scotland","volume":"341","author":"Strang","year":"2010","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.therap.2018.09.070_bib0255","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1093\/pubmed\/fdl059","article-title":"Changes to the daily pattern of methadone-related deaths in England and Wales, 1993\u20132003","volume":"28","author":"Morgan","year":"2006","journal-title":"J Public Health (Oxf)"},{"issue":"1\u20133","key":"10.1016\/j.therap.2018.09.070_bib0260","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.forsciint.2012.11.010","article-title":"Methadone-related deaths in Norway","volume":"224","author":"Bernard","year":"2013","journal-title":"Forensic Sci Int"},{"issue":"2","key":"10.1016\/j.therap.2018.09.070_bib0265","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2515\/therapie:2003017","article-title":"Pharmacologic criteria for medical substitution in opiate dependence","volume":"58","author":"Montastruc","year":"2003","journal-title":"Therapie"},{"issue":"4\u00a0Pt 1","key":"10.1016\/j.therap.2018.09.070_bib0270","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0013-7006(06)76190-5","article-title":"Methadone: from pharmacokinetic profile to clinical pharmacology","volume":"32","author":"Vazquez","year":"2006","journal-title":"Encephale"},{"key":"10.1016\/j.therap.2018.09.070_bib0275","article-title":"Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.therap.2018.09.070_bib0280","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c5475","article-title":"Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database","volume":"341","author":"Cornish","year":"2010","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.therap.2018.09.070_bib0285","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2515\/therapie\/2013022","article-title":"Opiate substitution treatment's cycles in a five-year followed-up cohort in ambulatory practice","volume":"68","author":"Dupouy","year":"2013","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2018.09.070_bib0145","article-title":"Temporary approval for intranasal naloxone: setting up in a French addiction center","author":"Barr\u00e9","year":"2018","journal-title":"Therapie"}],"container-title":["Therapies"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595718302178?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595718302178?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T18:52:58Z","timestamp":1758567178000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595718302178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S0040595718302178"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2018.09.070","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Am\u00e9liorer la balance b\u00e9n\u00e9fices\/risques de la m\u00e9thadone en respectant ses sp\u00e9cificit\u00e9s pharmacologiques","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2018.09.070","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}